User login
TOPLINE:
Anti-osteoporosis medications reduce fracture risk similarly, regardless of whether patients are younger or older than 70 years.
METHODOLOGY:
- Investigators conducted the study as part of a to assess bone mineral density as a surrogate marker for fracture risk.
- Analyses used individual patient data from 23 randomized placebo-controlled trials of anti-osteoporosis medications (11 of bisphosphonates, four of selective estrogen receptor modulators, three of anabolic medications, two of hormone replacement therapy, and one each of odanacatib, denosumab, and romosozumab).
- Overall, 43% of the included 123,164 patients were aged 70 years or older.
- The main outcomes were fractures and bone mineral density.
TAKEAWAY:
- There was a similar benefit regardless of age when it came to the reduction in risks for hip fracture (odds ratio, 0.65 vs 0.72; P for interaction = .50) and any fracture (odds ratio, 0.72 vs 0.70; P for interaction = .20).
- Findings were comparable in analyses restricted to bisphosphonate trials, except that the reduction in hip fracture risk was greater among the younger group (hazard ratio, 0.44 vs 0.79; P for interaction = .02).
- The benefit of anti-osteoporosis medication in increasing hip and spine bone mineral density at 24 months was significantly greater among the older patients.
IN PRACTICE:
Taken together, the study results “strongly support treatment in those over age 70,” the authors wrote. “These are important findings with potential impact in patient treatment since it goes against a common misconception that medications are less effective in older people,” they added.
SOURCE:
The study was led by Marian Schini, MD, PhD, FHEA, University of Sheffield, England, and was published online in the Journal of Bone and Mineral Research.
LIMITATIONS:
Limitations included a preponderance of female patients (99%), possible residual confounding, a lack of analysis of adverse effects, and potentially different findings using alternate age cutoffs.
DISCLOSURES:
The study was funded by the American Society for Bone Mineral Research. Some authors disclosed affiliations with companies that manufacture anti-osteoporosis drugs.
A version of this article appeared on Medscape.com.
TOPLINE:
Anti-osteoporosis medications reduce fracture risk similarly, regardless of whether patients are younger or older than 70 years.
METHODOLOGY:
- Investigators conducted the study as part of a to assess bone mineral density as a surrogate marker for fracture risk.
- Analyses used individual patient data from 23 randomized placebo-controlled trials of anti-osteoporosis medications (11 of bisphosphonates, four of selective estrogen receptor modulators, three of anabolic medications, two of hormone replacement therapy, and one each of odanacatib, denosumab, and romosozumab).
- Overall, 43% of the included 123,164 patients were aged 70 years or older.
- The main outcomes were fractures and bone mineral density.
TAKEAWAY:
- There was a similar benefit regardless of age when it came to the reduction in risks for hip fracture (odds ratio, 0.65 vs 0.72; P for interaction = .50) and any fracture (odds ratio, 0.72 vs 0.70; P for interaction = .20).
- Findings were comparable in analyses restricted to bisphosphonate trials, except that the reduction in hip fracture risk was greater among the younger group (hazard ratio, 0.44 vs 0.79; P for interaction = .02).
- The benefit of anti-osteoporosis medication in increasing hip and spine bone mineral density at 24 months was significantly greater among the older patients.
IN PRACTICE:
Taken together, the study results “strongly support treatment in those over age 70,” the authors wrote. “These are important findings with potential impact in patient treatment since it goes against a common misconception that medications are less effective in older people,” they added.
SOURCE:
The study was led by Marian Schini, MD, PhD, FHEA, University of Sheffield, England, and was published online in the Journal of Bone and Mineral Research.
LIMITATIONS:
Limitations included a preponderance of female patients (99%), possible residual confounding, a lack of analysis of adverse effects, and potentially different findings using alternate age cutoffs.
DISCLOSURES:
The study was funded by the American Society for Bone Mineral Research. Some authors disclosed affiliations with companies that manufacture anti-osteoporosis drugs.
A version of this article appeared on Medscape.com.
TOPLINE:
Anti-osteoporosis medications reduce fracture risk similarly, regardless of whether patients are younger or older than 70 years.
METHODOLOGY:
- Investigators conducted the study as part of a to assess bone mineral density as a surrogate marker for fracture risk.
- Analyses used individual patient data from 23 randomized placebo-controlled trials of anti-osteoporosis medications (11 of bisphosphonates, four of selective estrogen receptor modulators, three of anabolic medications, two of hormone replacement therapy, and one each of odanacatib, denosumab, and romosozumab).
- Overall, 43% of the included 123,164 patients were aged 70 years or older.
- The main outcomes were fractures and bone mineral density.
TAKEAWAY:
- There was a similar benefit regardless of age when it came to the reduction in risks for hip fracture (odds ratio, 0.65 vs 0.72; P for interaction = .50) and any fracture (odds ratio, 0.72 vs 0.70; P for interaction = .20).
- Findings were comparable in analyses restricted to bisphosphonate trials, except that the reduction in hip fracture risk was greater among the younger group (hazard ratio, 0.44 vs 0.79; P for interaction = .02).
- The benefit of anti-osteoporosis medication in increasing hip and spine bone mineral density at 24 months was significantly greater among the older patients.
IN PRACTICE:
Taken together, the study results “strongly support treatment in those over age 70,” the authors wrote. “These are important findings with potential impact in patient treatment since it goes against a common misconception that medications are less effective in older people,” they added.
SOURCE:
The study was led by Marian Schini, MD, PhD, FHEA, University of Sheffield, England, and was published online in the Journal of Bone and Mineral Research.
LIMITATIONS:
Limitations included a preponderance of female patients (99%), possible residual confounding, a lack of analysis of adverse effects, and potentially different findings using alternate age cutoffs.
DISCLOSURES:
The study was funded by the American Society for Bone Mineral Research. Some authors disclosed affiliations with companies that manufacture anti-osteoporosis drugs.
A version of this article appeared on Medscape.com.
<!--$RCSfile: InCopy_agile.xsl,v $ $Revision: 1.35 $-->
<!--$RCSfile: drupal.xsl,v $ $Revision: 1.7 $-->
<root generator="drupal.xsl" gversion="1.7"> <header> <fileName>167458</fileName> <TBEID>0C04F3FC.SIG</TBEID> <TBUniqueIdentifier>MD_0C04F3FC</TBUniqueIdentifier> <newsOrJournal>News</newsOrJournal> <publisherName>Frontline Medical Communications</publisherName> <storyname/> <articleType>2</articleType> <TBLocation>QC Done-All Pubs</TBLocation> <QCDate>20240326T131610</QCDate> <firstPublished>20240326T131822</firstPublished> <LastPublished>20240326T131822</LastPublished> <pubStatus qcode="stat:"/> <embargoDate/> <killDate/> <CMSDate>20240326T131821</CMSDate> <articleSource/> <facebookInfo/> <meetingNumber/> <byline>Susan London</byline> <bylineText>SUSAN LONDON</bylineText> <bylineFull>SUSAN LONDON</bylineFull> <bylineTitleText/> <USOrGlobal/> <wireDocType/> <newsDocType>News</newsDocType> <journalDocType/> <linkLabel/> <pageRange/> <citation/> <quizID/> <indexIssueDate/> <itemClass qcode="ninat:text"/> <provider qcode="provider:imng"> <name>IMNG Medical Media</name> <rightsInfo> <copyrightHolder> <name>Frontline Medical News</name> </copyrightHolder> <copyrightNotice>Copyright (c) 2015 Frontline Medical News, a Frontline Medical Communications Inc. company. All rights reserved. This material may not be published, broadcast, copied, or otherwise reproduced or distributed without the prior written permission of Frontline Medical Communications Inc.</copyrightNotice> </rightsInfo> </provider> <abstract/> <metaDescription>Anti-osteoporosis medications reduce fracture risk similarly, regardless of whether patients are younger or older than 70 years.</metaDescription> <articlePDF/> <teaserImage/> <teaser>Age is not a significant factor in reducing fracture risk; medications similarly effective in range of ages, finds study.</teaser> <title>Anti-Osteoporosis Drugs Found Just as Effective in Seniors</title> <deck/> <disclaimer/> <AuthorList/> <articleURL/> <doi/> <pubMedID/> <publishXMLStatus/> <publishXMLVersion>1</publishXMLVersion> <useEISSN>0</useEISSN> <urgency/> <pubPubdateYear/> <pubPubdateMonth/> <pubPubdateDay/> <pubVolume/> <pubNumber/> <wireChannels/> <primaryCMSID/> <CMSIDs/> <keywords/> <seeAlsos/> <publications_g> <publicationData> <publicationCode>rn</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> <publicationData> <publicationCode>endo</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> <publicationData> <publicationCode>fp</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> <publicationData> <publicationCode>im</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> </publications_g> <publications> <term canonical="true">26</term> <term>34</term> <term>15</term> <term>21</term> </publications> <sections> <term canonical="true">39313</term> </sections> <topics> <term canonical="true">266</term> <term>290</term> </topics> <links/> </header> <itemSet> <newsItem> <itemMeta> <itemRole>Main</itemRole> <itemClass>text</itemClass> <title>Anti-Osteoporosis Drugs Found Just as Effective in Seniors</title> <deck/> </itemMeta> <itemContent> <h2>TOPLINE:</h2> <p>Anti-osteoporosis medications reduce fracture risk similarly, regardless of whether patients are younger or older than 70 years.</p> <h2>METHODOLOGY:</h2> <ul class="body"> <li>Investigators conducted the study as part of a to assess bone mineral density as a surrogate marker for fracture risk.</li> <li>Analyses used individual patient data from 23 randomized placebo-controlled trials of anti-osteoporosis medications (11 of bisphosphonates, four of selective estrogen receptor modulators, three of anabolic medications, two of hormone replacement therapy, and one each of odanacatib, denosumab, and romosozumab).</li> <li>Overall, 43% of the included 123,164 patients were aged 70 years or older.</li> <li>The main outcomes were fractures and bone mineral density.</li> </ul> <h2>TAKEAWAY:</h2> <ul class="body"> <li/> <li>There was a similar benefit regardless of age when it came to the reduction in risks for hip fracture (odds ratio, 0.65 vs 0.72; <em>P</em> for interaction = .50) and any fracture (odds ratio, 0.72 vs 0.70; <em>P</em> for interaction = .20).</li> <li>Findings were comparable in analyses restricted to bisphosphonate trials, except that the reduction in hip fracture risk was greater among the younger group (hazard ratio, 0.44 vs 0.79; <em>P</em> for interaction = .02).</li> <li>The benefit of anti-osteoporosis medication in increasing hip and spine bone mineral density at 24 months was significantly greater among the older patients.</li> </ul> <h2>IN PRACTICE:</h2> <p>Taken together, the study results “strongly support treatment in those over age 70,” the authors wrote. “These are important findings with potential impact in patient treatment since it goes against a common misconception that medications are less effective in older people,” they added.</p> <h2>SOURCE:</h2> <p>The study was led by Marian Schini, MD, PhD, FHEA, University of Sheffield, England, and was <a href="https://academic.oup.com/jbmr/advance-article/doi/10.1093/jbmr/zjae040/7631748">published online</a> in the <em>Journal of Bone and Mineral Research</em>.</p> <h2>LIMITATIONS:</h2> <p>Limitations included a preponderance of female patients (99%), possible residual confounding, a lack of analysis of adverse effects, and potentially different findings using alternate age cutoffs.</p> <h2>DISCLOSURES:</h2> <p>The study was funded by the American Society for Bone Mineral Research. Some authors disclosed affiliations with companies that manufacture anti-osteoporosis drugs.</p> <p> <em>A version of this article appeared on <span class="Hyperlink"><a href="https://www.medscape.com/s/viewarticle/anti-osteoporosis-drugs-found-just-effective-seniors-2024a100058e?src=">Medscape.com</a></span>.</em> </p> </itemContent> </newsItem> <newsItem> <itemMeta> <itemRole>teaser</itemRole> <itemClass>text</itemClass> <title/> <deck/> </itemMeta> <itemContent> </itemContent> </newsItem> </itemSet></root>